How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience.

Emanuela Marchesi, Celeste Cagnazzo, Irene Quattrini, Martina Piccinni Leopardi, Chiara Villa, Giovanni Grignani, Lorenzo D'Ambrosio, Silvia Stacchiotti, Paolo Giovanni Casali, Piero Picci

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The Italian Sarcoma Group (ISG) is a nonprofit group of professionals established in 1997 aimed to improve the quality of care and promote the independent research in sarcomas. The increased regulatory requirements, the chance to increase the number of trials with other cooperative groups and an interest from pharmaceutical companies in supporting independent research, generated the need of an internal service for research management. METHODS AND RESULTS: In 2010, ISG implemented in its organization a Clinical Trial Unit (CTU). The CTU was appointed to fully manage Clinical Trial Operations, to guarantee regulation compliance and provide a central support to the investigators, fostering a collaboration both at national and international level. In 2016 ISG promoted 25 studies in about 120 centers, with a fivefold increase in the last 5 years: 68% were interventional and 32% observational. Nine of the 17 interventional studies (52%) were supported by pharmaceutical companies, while 4 (24%) were funded by European Commission within specific projects on sarcomas and 4 (24%) were supported by the ISG itself. CONCLUSION: The contribution of ISG researchers to the international community was striking from the earliest years of the ISG creation. The challenges of the regulatory clinical research scenario, which imposes solid and hard-fast methodology with deep knowledge and expertise, highlighted the need to identify qualified and dedicated experts able to run and follow the multifaceted aspects of trials. Our analysis demonstrated how this model has led to a growth in competitiveness of the group. The collaboration between clinicians and CTU made possible to support the research with high scientific and ethical standards and to increase the number of trials, sites and overall enrolled patients. The reduced time for approvals, the continuous support to sites, the increased speed in data collection and analysis make the ISG research attractive for pharmaceutical industries, despite the problems that have characterized the independent research in the last years. The ability to fully manage and oversight Clinical Operations and the high quality of delivered services, have led the ISG to be recognized as a reliable partner and coordinator within the international sarcoma networks.
Original languageEnglish
Pages (from-to)4
Number of pages1
JournalClinical sarcoma research
Volume7
Publication statusPublished - 2017

Fingerprint

Sarcoma
Clinical Trials
Research
Neoplasms
Research Personnel
Public Opinion
Foster Home Care
Quality of Health Care
Drug Industry
Pharmaceutical Preparations
Compliance

Cite this

How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience. / Marchesi, Emanuela; Cagnazzo, Celeste; Quattrini, Irene; Leopardi, Martina Piccinni; Villa, Chiara; Grignani, Giovanni; D'Ambrosio, Lorenzo; Stacchiotti, Silvia; Casali, Paolo Giovanni; Picci, Piero.

In: Clinical sarcoma research, Vol. 7, 2017, p. 4.

Research output: Contribution to journalArticle

@article{ebd7c6d0b8774d6dadb6ef0b0660e7dd,
title = "How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience.",
abstract = "BACKGROUND: The Italian Sarcoma Group (ISG) is a nonprofit group of professionals established in 1997 aimed to improve the quality of care and promote the independent research in sarcomas. The increased regulatory requirements, the chance to increase the number of trials with other cooperative groups and an interest from pharmaceutical companies in supporting independent research, generated the need of an internal service for research management. METHODS AND RESULTS: In 2010, ISG implemented in its organization a Clinical Trial Unit (CTU). The CTU was appointed to fully manage Clinical Trial Operations, to guarantee regulation compliance and provide a central support to the investigators, fostering a collaboration both at national and international level. In 2016 ISG promoted 25 studies in about 120 centers, with a fivefold increase in the last 5 years: 68{\%} were interventional and 32{\%} observational. Nine of the 17 interventional studies (52{\%}) were supported by pharmaceutical companies, while 4 (24{\%}) were funded by European Commission within specific projects on sarcomas and 4 (24{\%}) were supported by the ISG itself. CONCLUSION: The contribution of ISG researchers to the international community was striking from the earliest years of the ISG creation. The challenges of the regulatory clinical research scenario, which imposes solid and hard-fast methodology with deep knowledge and expertise, highlighted the need to identify qualified and dedicated experts able to run and follow the multifaceted aspects of trials. Our analysis demonstrated how this model has led to a growth in competitiveness of the group. The collaboration between clinicians and CTU made possible to support the research with high scientific and ethical standards and to increase the number of trials, sites and overall enrolled patients. The reduced time for approvals, the continuous support to sites, the increased speed in data collection and analysis make the ISG research attractive for pharmaceutical industries, despite the problems that have characterized the independent research in the last years. The ability to fully manage and oversight Clinical Operations and the high quality of delivered services, have led the ISG to be recognized as a reliable partner and coordinator within the international sarcoma networks.",
author = "Emanuela Marchesi and Celeste Cagnazzo and Irene Quattrini and Leopardi, {Martina Piccinni} and Chiara Villa and Giovanni Grignani and Lorenzo D'Ambrosio and Silvia Stacchiotti and Casali, {Paolo Giovanni} and Piero Picci",
year = "2017",
language = "English",
volume = "7",
pages = "4",
journal = "Clinical sarcoma research",
issn = "2045-3329",

}

TY - JOUR

T1 - How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience.

AU - Marchesi, Emanuela

AU - Cagnazzo, Celeste

AU - Quattrini, Irene

AU - Leopardi, Martina Piccinni

AU - Villa, Chiara

AU - Grignani, Giovanni

AU - D'Ambrosio, Lorenzo

AU - Stacchiotti, Silvia

AU - Casali, Paolo Giovanni

AU - Picci, Piero

PY - 2017

Y1 - 2017

N2 - BACKGROUND: The Italian Sarcoma Group (ISG) is a nonprofit group of professionals established in 1997 aimed to improve the quality of care and promote the independent research in sarcomas. The increased regulatory requirements, the chance to increase the number of trials with other cooperative groups and an interest from pharmaceutical companies in supporting independent research, generated the need of an internal service for research management. METHODS AND RESULTS: In 2010, ISG implemented in its organization a Clinical Trial Unit (CTU). The CTU was appointed to fully manage Clinical Trial Operations, to guarantee regulation compliance and provide a central support to the investigators, fostering a collaboration both at national and international level. In 2016 ISG promoted 25 studies in about 120 centers, with a fivefold increase in the last 5 years: 68% were interventional and 32% observational. Nine of the 17 interventional studies (52%) were supported by pharmaceutical companies, while 4 (24%) were funded by European Commission within specific projects on sarcomas and 4 (24%) were supported by the ISG itself. CONCLUSION: The contribution of ISG researchers to the international community was striking from the earliest years of the ISG creation. The challenges of the regulatory clinical research scenario, which imposes solid and hard-fast methodology with deep knowledge and expertise, highlighted the need to identify qualified and dedicated experts able to run and follow the multifaceted aspects of trials. Our analysis demonstrated how this model has led to a growth in competitiveness of the group. The collaboration between clinicians and CTU made possible to support the research with high scientific and ethical standards and to increase the number of trials, sites and overall enrolled patients. The reduced time for approvals, the continuous support to sites, the increased speed in data collection and analysis make the ISG research attractive for pharmaceutical industries, despite the problems that have characterized the independent research in the last years. The ability to fully manage and oversight Clinical Operations and the high quality of delivered services, have led the ISG to be recognized as a reliable partner and coordinator within the international sarcoma networks.

AB - BACKGROUND: The Italian Sarcoma Group (ISG) is a nonprofit group of professionals established in 1997 aimed to improve the quality of care and promote the independent research in sarcomas. The increased regulatory requirements, the chance to increase the number of trials with other cooperative groups and an interest from pharmaceutical companies in supporting independent research, generated the need of an internal service for research management. METHODS AND RESULTS: In 2010, ISG implemented in its organization a Clinical Trial Unit (CTU). The CTU was appointed to fully manage Clinical Trial Operations, to guarantee regulation compliance and provide a central support to the investigators, fostering a collaboration both at national and international level. In 2016 ISG promoted 25 studies in about 120 centers, with a fivefold increase in the last 5 years: 68% were interventional and 32% observational. Nine of the 17 interventional studies (52%) were supported by pharmaceutical companies, while 4 (24%) were funded by European Commission within specific projects on sarcomas and 4 (24%) were supported by the ISG itself. CONCLUSION: The contribution of ISG researchers to the international community was striking from the earliest years of the ISG creation. The challenges of the regulatory clinical research scenario, which imposes solid and hard-fast methodology with deep knowledge and expertise, highlighted the need to identify qualified and dedicated experts able to run and follow the multifaceted aspects of trials. Our analysis demonstrated how this model has led to a growth in competitiveness of the group. The collaboration between clinicians and CTU made possible to support the research with high scientific and ethical standards and to increase the number of trials, sites and overall enrolled patients. The reduced time for approvals, the continuous support to sites, the increased speed in data collection and analysis make the ISG research attractive for pharmaceutical industries, despite the problems that have characterized the independent research in the last years. The ability to fully manage and oversight Clinical Operations and the high quality of delivered services, have led the ISG to be recognized as a reliable partner and coordinator within the international sarcoma networks.

M3 - Article

VL - 7

SP - 4

JO - Clinical sarcoma research

JF - Clinical sarcoma research

SN - 2045-3329

ER -